Neurofeedback and Biofeedback

Operant learning—with human interpretation

When the display changes reliably after a desired physiological pattern, that change can act as reinforcement. Over repeated trials, useful strategies may become easier to reproduce. Neurofeedback research also implicates attention, motivation, interoception, reward learning, metacognition and explicit strategy formation; “the brain rewards itself” is too simple.¹

Learning is not guaranteed. A 2025 meta-analysis of 55 participant groups found that acquisition varied with the measurement method, feedback complexity, rehearsal and targeted EEG feature. The field calls persistent failure to modulate the target the neurofeedback inefficacy problem—a reminder that non-response may reflect the protocol, signal, instruction, person or analysis rather than deficient effort.³

These outcomes can dissociate. Successful signal regulation without symptom change is scientifically informative. Symptom improvement without target learning may point to nonspecific benefits. A responsible report does not erase either result.

Frequency bands are summaries—not substances

EEG software often displays delta, theta, alpha, beta and gamma power. These are conventional frequency ranges applied to a continuous, mixed signal. Alpha can vary with eye closure and sensory attention; theta can vary with drowsiness, memory and control; high-frequency activity is especially vulnerable to muscle artifact. A theta-to-beta ratio cannot by itself diagnose ADHD or identify intelligence.

Modern spectral methods also distinguish oscillatory peaks from the aperiodic background of the signal. If that background changes, a band-power ratio can change even when the presumed rhythm has not changed in the expected way.⁵

Controls must match the question

A waitlist asks whether the complete programme is better than waiting. An active control can match time, coaching and engagement. A sham control may replay another person’s signal, use delayed feedback or make reward independent of the current target. Each has weaknesses: sham may be detected; a poorly designed active control may be less credible; a “placebo” can still contain helpful breathing or attention practice.

Blinded ratings matter when expectations are strong. Objective tasks can help, but they also have practice effects and may not represent everyday functioning. The CRED-nf consensus therefore recommends prespecifying the feedback signal and control condition, testing regulation success, reporting adverse effects and separating experimental, behavioural and clinical outcomes.²

1. DefineOne observable target and one meaningful outcome
2. BaselineRepeated measurement before training
3. ControlCredible sham or active comparison
4. BlindOutcome assessors where possible
5. TransferTest without feedback
6. Follow upAsk whether benefit lasts

The dashboard is part of the intervention, not the verdict.

What this means for families and adults

• Do not replace an effective medication, behavioural intervention, educational support or clinical plan on the basis of an EEG map or testimonial.
• Ask whether the goal is symptom relief, a specific cognitive process, self-awareness, medication reduction or something else—and measure that outcome directly.
• Expect providers to explain the exact protocol, comparison evidence, likely time and cost, non-response criteria and how benefit will be distinguished from repeated attention.
• Treat “personalized” as a hypothesis requiring validation, not as proof that any qEEG-selected target is uniquely correct.

Some people may still value the structured practice, agency or attention to internal state. That value should be described honestly rather than converted into a universal disease-treatment claim.

Evidence is encouraging, but not uniform

A 2017 meta-analysis found large average reductions in self-reported stress and anxiety, but included only 24 studies and 484 participants and called for better controlled research.¹⁰ A broader 2020 review also reported benefits across emotional, physical and performance outcomes, while emphasizing considerable variation in protocols and applications.¹¹

A newer review of remote HRV biofeedback included 18 studies and 1,352 participants. It found improvement in depressive symptoms and HRV, but no significant pooled effect on perceived stress; anxiety evidence came from only three studies, two nonrandomized and at high risk of bias. Only one included study was rated low risk of bias.¹² This does not cancel earlier findings—it shows why population, comparator, protocol and outcome must be named.

Why an inactive comparison can exaggerate confidence

Feedback programmes supply scheduled contact, a coherent explanation, repeated practice and a sense of agency. Those ingredients may be genuinely helpful. Yet an effect against waiting does not reveal whether the displayed brain signal was necessary. Sham and active controls become especially important when the intervention is expensive, makes disease claims or asks patients to delay established care.

Clinical translation requires more than a significant average

Readers should look for absolute change, responder definitions, everyday function, adverse effects, durability and the range of individual outcomes. A statistically significant group difference can be too small to matter; a null average can conceal a subgroup worth studying. Subgroup claims, however, should be tested prospectively rather than invented after results are known.

Consumer mindfulness neurofeedback illustrates the gap. A 2025 meta-analysis found a modest reduction in psychological distress, possibly placebo-related, but no conclusive improvement in cognition, mindfulness, physiological health or the proposed neural targets. Nineteen of 21 included studies did not assess adverse events.²⁰

This does not make every consumer device useless. A headset can supply a timer, ritual, reminder or responsive sound that encourages practice. The honest description is “technology supporting a routine,” not “direct control of the brain” unless target engagement and added benefit have been demonstrated.

Technology is most humane when it helps a mind express itself—not when a score is allowed to define the mind.

Use comfort as a constraint

A starting pace near five to seven breaths per minute is common in research, but it is not a universal prescription. Breathing should remain smooth and modest. Light-headedness, tingling, air hunger, chest discomfort or rising panic are reasons to return to ordinary breathing and stop the session. People with significant cardiac, respiratory, fainting, pregnancy-related or other medical concerns should discuss paced breathing with a qualified clinician.

Measure what matters after the display closes

• Could you reproduce the steadier breathing without visual guidance?
• Did recovery after an ordinary stressor become faster or easier?
• Did sleep, concentration or anxiety improve consistently—not just during the attractive exercise?
• Did the practice create dependence on checking a score, frustration or avoidance?

The SIGNAL checklist

Be cautious with universal brain maps

Group averages do not define an ideal brain for every individual. A deviation from a reference database may reflect age, alertness, medication, sleep, eye state, recording choices or ordinary variation. A qEEG can be a measurement tool; it should not be used as a stand-alone diagnosis, personality test or deterministic explanation for every symptom.

Likewise, “FDA registered,” “medical grade,” “clinically tested” and “uses an FDA-cleared sensor” are not interchangeable with clearance or approval of the exact device for the exact claim. Ask for the regulatory product code, intended use and decision record.

Medical-device status follows intended use

United States regulation defines a biofeedback device as an instrument providing a visual or auditory signal corresponding to physiological parameters so that a patient can learn voluntary control. The narrow exemption from premarket notification applies under specified conditions to prescription, battery-powered devices indicated for relaxation training and muscle re-education; broader diagnosis or treatment claims can change the regulatory pathway.²¹

FDA’s current classification lists biofeedback devices under Class II and recognizes IEEE 2010-2023, a technical recommended practice for EEG neurofeedback systems. Recognition of a standard can support device quality; it does not prove that a particular protocol treats ADHD, anxiety or another disorder.²²

In the European Union, whether software or hardware is a medical device depends on its intended medical purpose under the Medical Device Regulation. Data processing must also comply with the General Data Protection Regulation when personal data are involved, including health or biometric data under applicable conditions.²³²⁴

A modern neural-data standard

UNESCO’s 2025 Recommendation on the Ethics of Neurotechnology extends concern beyond direct neural recordings to indirect data that can support mental-state inference. It calls for prior, free and informed consent, data minimization, purpose limitation, security and the ability to access, correct, erase or suspend processing. It also rejects coercive or manipulative use and gives special attention to workplaces and children.²⁵

The OECD similarly recommends clear information about collection and use, meaningful choices over sharing, access and deletion, protection from discrimination and avoidance of hype. Brain-related data should not become a hidden condition of employment, insurance, education or ordinary participation.²⁶

Monitor the whole person, not only the target

Headache, fatigue, frustration, dizziness during breathing practice, sleep disruption, agitation, increased anxiety or other unwanted changes should be recorded rather than rebranded as proof that the brain is “reorganizing.” Adverse-event reporting has often been weak: the consumer mindfulness review found that most included studies did not assess it at all.²⁰

Clinical programmes should define who supervises emerging symptoms, when training pauses and how existing care is coordinated. A user should never be pressured to continue because stopping would supposedly reveal resistance, low intelligence or insufficient motivation.

1. Sitaram et al. Closed-loop brain training: the science of neurofeedback (2017).
2. Ros et al. Consensus on the reporting and experimental design of clinical and cognitive-behavioural neurofeedback studies: CRED-nf checklist (2020).
3. Galang, Velásquez, Elcin et al. Systematic review and meta-analysis of the relationships between real-time neurofeedback training parameters and acquisition of neural modulation (2025).
4. Logothetis et al. Neurophysiological investigation of the basis of the fMRI signal (2001).
5. Donoghue, Dominguez & Voytek. Electrophysiological frequency band ratio measures conflate periodic and aperiodic neural activity (2020).
6. Westwood et al., European ADHD Guidelines Group. Neurofeedback for attention-deficit/hyperactivity disorder: A systematic review and meta-analysis (2025).
7. Arnold et al., Neurofeedback Collaborative Group. Double-blind placebo-controlled randomized clinical trial of neurofeedback for ADHD with 13-month follow-up (2021).
8. Wang et al. A double-blind randomized controlled trial of personalized upper-alpha neurofeedback in children with ADHD (2026).
9. Lehrer & Gevirtz. Heart rate variability biofeedback: How and why does it work? (2014).
10. Goessl, Curtiss & Hofmann. The effect of heart rate variability biofeedback training on stress and anxiety: A meta-analysis (2017).
11. Lehrer et al. Heart rate variability biofeedback improves emotional and physical health and performance: A systematic review and meta-analysis (2020).
12. Vann-Adibe et al. Efficacy and methodology of remote heart rate variability biofeedback interventions for mental health: A systematic review and meta-analysis (published 2025; volume 2026).
13. Lalanza et al. Methods for heart rate variability biofeedback: A systematic review and guidelines (2023).
14. Sumińska, Rynkiewicz & Szulczewski. Resonance frequency versus fixed 0.1 Hz breathing in HRV biofeedback: A four-week randomized comparison (2026).
15. Berman et al. Systematic review and meta-analysis of neurofeedback training efficacy and neural mechanisms in the treatment of posttraumatic stress disorder (2025).
16. Khaleghi et al. Effectiveness of fMRI-based neurofeedback therapy on depression: A systematic review (2025).
17. Zhang et al. Self-navigating the “Island of Reil”: A systematic review of real-time fMRI neurofeedback training of insula activity (2025).
18. Schabus et al. Better than sham? A double-blind placebo-controlled neurofeedback study in primary insomnia (2017).
19. Butet et al. EEG-fMRI neurofeedback versus motor imagery after stroke: A randomized controlled trial (2025).
20. Treves & Goldberg. Consumer-grade neurofeedback with mindfulness meditation: Meta-analysis (2025).
21. US Electronic Code of Federal Regulations. 21 CFR § 882.5050—Biofeedback device (current electronic edition).
22. US Food and Drug Administration. Product classification: Biofeedback device, product code HCC; and recognition of IEEE Std 2010-2023 for EEG neurofeedback systems (accessed 2026).
23. European Parliament and Council. Regulation (EU) 2017/745 on medical devices (consolidated official text).
24. European Parliament and Council. Regulation (EU) 2016/679: General Data Protection Regulation (official text).
25. UNESCO. Recommendation on the Ethics of Neurotechnology (adopted 2025).
26. OECD. Recommendation on Responsible Innovation in Neurotechnology (2019).

Educational note: This article explains general evidence, measurement and ethical principles. It does not diagnose a condition, interpret an individual EEG, prescribe breathing or neurofeedback treatment, or replace medical, psychological, rehabilitation or data-protection advice. Device software, intended use, personal health and local law materially change what is appropriate.

• Flow States and Peak Performance
• Meditative States
• Sleep and Dreams
• Hypnosis and Suggestibility
• Psychedelic Research
• Neurofeedback and Biofeedback